Company newsMRNA
Explain this story: Bernstein reiterates Moderna stock rating on mRNA platform progress
Bernstein SocGen Group has reiterated a Market Perform rating and a $45.00 price target for Moderna Inc. (NASDAQ: MRNA) shares, despite the stock's significant surge over the past year. Analysts highlighted that Intismeran validates the broader mRNA therapeutics platform, with promising melanoma data expected. However, InvestingPro analysis suggests the stock is currently overvalued, leading to mixed sentiment among other analysts.
OtherInvesting.comSector and industry: HealthcareBiotechnologyTell me moreShow less
We have not explained this story yet. The original headline, summary and link are below.
Bernstein SocGen Group has reiterated a Market Perform rating and a $45.00 price target for Moderna Inc. (NASDAQ: MRNA) shares, despite the stock's significant surge over the past year. Analysts highlighted that Intismeran validates the broader mRNA therapeutics platform, with promising melanoma data expected. However, InvestingPro analysis suggests the stock is currently overvalued, leading to mixed sentiment among other analysts.
Article tone: Neutral This describes the words the journalist used. It is not a prediction, and not advice.